Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

The inherent limitations of
using tumour tissues for genomic profiling has led to the need for a more
efficient, easily accessible yet accurate method of evaluating biomarkers to
facilitate personalised medicine. At the ESMO Asia Colloquia chaired by
Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of
precision oncology shared insights on the diagnostic,
prognostic and predictive values of tumour-derived blood biomarkers (liquid
biopsy) for the management of various cancer types.

Liquid biopsy in the management of solid tumours

13 Apr 2020

The inherent limitations of using tumour tissues for genomic profiling has led to the need for a more efficient, easily accessible yet accurate method of evaluating biomarkers to facilitate personalised medicine. At the ESMO Asia Colloquia chaired by Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of precision oncology shared insights on the diagnostic, prognostic and predictive values of tumour-derived blood biomarkers (liquid biopsy) for the management of various cancer types.

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

The inherent limitations of
using tumour tissues for genomic profiling has led to the need for a more
efficient, easily accessible yet accurate method of evaluating biomarkers to
facilitate personalised medicine. At the ESMO Asia Colloquia chaired by
Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of
precision oncology shared insights on the diagnostic,
prognostic and predictive values of tumour-derived blood biomarkers (liquid
biopsy) for the management of various cancer types.